AnaptysBio (NASDAQ:ANAB) Research Coverage Started at SVB Leerink

SVB Leerink started coverage on shares of AnaptysBio (NASDAQ:ANAB) in a research note released on Tuesday, MarketBeat.com reports. The brokerage issued an outperform rating and a $47.00 price target on the biotechnology company’s stock.

A number of other research analysts have also weighed in on the stock. Wells Fargo & Company started coverage on shares of AnaptysBio in a research report on Thursday, April 11th. They set an overweight rating and a $56.00 price target on the stock. Wedbush raised shares of AnaptysBio from a neutral rating to an outperform rating and lifted their price objective for the stock from $20.00 to $34.00 in a research report on Tuesday, March 12th. BTIG Research started coverage on shares of AnaptysBio in a research report on Monday, February 26th. They issued a buy rating and a $55.00 price objective on the stock. JPMorgan Chase & Co. lowered their price objective on shares of AnaptysBio from $30.00 to $28.00 and set a neutral rating on the stock in a research report on Monday, April 1st. Finally, Stifel Nicolaus started coverage on shares of AnaptysBio in a research report on Wednesday, February 21st. They issued a buy rating and a $50.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average target price of $46.22.

AnaptysBio Price Performance

ANAB opened at $19.83 on Tuesday. The company’s 50-day moving average is $23.31 and its 200 day moving average is $20.54. AnaptysBio has a fifty-two week low of $13.36 and a fifty-two week high of $27.50. The firm has a market capitalization of $530.65 million, a P/E ratio of -3.26 and a beta of -0.30.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.74) by $0.15. AnaptysBio had a negative net margin of 953.66% and a negative return on equity of 119.42%. The company had revenue of $9.01 million for the quarter, compared to analyst estimates of $3.28 million. On average, equities research analysts expect that AnaptysBio will post -6.25 earnings per share for the current year.

Insider Activity at AnaptysBio

In related news, CEO Daniel Faga sold 145,940 shares of the business’s stock in a transaction that occurred on Friday, March 22nd. The shares were sold at an average price of $22.78, for a total transaction of $3,324,513.20. Following the completion of the transaction, the chief executive officer now owns 752,087 shares of the company’s stock, valued at $17,132,541.86. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other AnaptysBio news, CFO Dennis Mulroy sold 3,065 shares of the business’s stock in a transaction that occurred on Tuesday, January 30th. The shares were sold at an average price of $23.63, for a total value of $72,425.95. Following the completion of the transaction, the chief financial officer now owns 964 shares of the company’s stock, valued at approximately $22,779.32. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Daniel Faga sold 145,940 shares of the business’s stock in a transaction that occurred on Friday, March 22nd. The stock was sold at an average price of $22.78, for a total transaction of $3,324,513.20. Following the completion of the transaction, the chief executive officer now directly owns 752,087 shares of the company’s stock, valued at approximately $17,132,541.86. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 157,005 shares of company stock valued at $3,586,199. Corporate insiders own 35.50% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC bought a new stake in shares of AnaptysBio in the 1st quarter worth approximately $38,000. Fisher Asset Management LLC lifted its holdings in shares of AnaptysBio by 0.7% in the 4th quarter. Fisher Asset Management LLC now owns 71,154 shares of the biotechnology company’s stock worth $1,524,000 after acquiring an additional 500 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of AnaptysBio by 2.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 231,754 shares of the biotechnology company’s stock worth $4,965,000 after acquiring an additional 5,472 shares during the last quarter. Palo Alto Investors LP lifted its holdings in shares of AnaptysBio by 59.3% in the 4th quarter. Palo Alto Investors LP now owns 686,882 shares of the biotechnology company’s stock worth $14,713,000 after acquiring an additional 255,658 shares during the last quarter. Finally, Octagon Capital Advisors LP bought a new stake in shares of AnaptysBio in the 4th quarter worth approximately $2,570,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.